MDM2 gene amplification in colorectal cancer is associated with disease progression at the primary site, but inversely correlated with distant metastasis

Genes Chromosomes and Cancer

Volumn 49, Issue 7, 2010, Pages 620-629

  Sugano, Nobuhiro ^a   Suda, Tetsuji ^a   Godai, Ten I ^a   Tsuchida, Kazuhito ^a   Shiozawa, Manabu ^a   Sekiguchi, Hironobu ^a   Yoshihara, Mitsuyo ^a   Matsukuma, Shoichi ^a   Sakuma, Yuji ^a   Tsuchiya, Eiju ^a   Kameda, Yoichi ^a   Akaike, Makoto ^a   Miyagi, Yohei ^a  

^a KANAGAWA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; PROTEIN P53;

ADULT; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; CENTROMERE; CHROMOSOME 12; COLORECTAL CANCER; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; DISTANT METASTASIS; ETHNICITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENOTYPE; GEOGRAPHY; HUMAN; HUMAN TISSUE; JAPANESE; MAJOR CLINICAL STUDY; MALE; MDM2 GENE; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TUMOR GENE;

COLORECTAL NEOPLASMS; GENE AMPLIFICATION; GENES, RAS; GENOTYPE; HUMANS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2;

EID: 77953194215     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20774     Document Type: Article

References (41)

1. Alhopuro P, Ylisaukko-Oja SK, Koskinen WJ, Bono P, Arola J, Järvinen HJ, Mecklin JP, Atula T, Kontio R, Mäkitie AA, Suominen S, Leivo I, Vahteristo P, Aaltonen LM, Aaltonen LA. 2005. The MDM2 promoter polymorphism SNP309T->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet 42:694-698.
2. Bartel F, Meye A, Würl P, Kappler M, Bache M, Lautenschläger C, Grünbaum U, Schmidt H, Taubert H. 2001. Amplification of the MDM2 gene, but not expression of splice variants of MDM2 MRNA, is associated with prognosis in soft tissue sarcoma. Int J Cancer 95:168-175.
3. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ. 2004. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591-602.
4. Bond GL, Menin C, Bertorelle R, Alhopuro P, Aaltonen LA, Levine AJ. 2006. MDM2 SNP309 accelerates colorectal tumour formation in women. J Med Genet 43:950-952. (Pubitemid 46080193)
5. Diep CB, Kleivi K, Ribeiro FR, Teixeira MR, Lindgjaerde OC, Lothe RA. 2006. The order of genetic events associated with colorectal cancer progression inferred from meta-analysis of copy number changes. Genes Chromosomes Cancer 45:31-41. (Pubitemid 46930859)
6. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM. 2000. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 275:8945-8951. (Pubitemid 30180252)
7. Forslund A, Zeng Z, Qin LX, Rosenberg S, Ndubuisi M, Pincas H, Gerald W, Notterman DA, Barany F, Paty PB. 2008. MDM2 gene amplification is correlated to tumor progression but not to the presence of SNP309 or TP53 mutational status in primary colorectal cancers. Mol Cancer Res 6:205-211. (Pubitemid 351342408)
8. Ganguli G, Wasylyk B. 2003. p53-independent functions of MDM2. Mol Cancer Res 1:1027-1035.
9. Hamilton SR, Aaltonen LA. 2000. WHO Classification of Tumors: Pathology and Genetics of Tumours of Digestive System. Lyon: IARC Press. 320 p.
10. Higashiyama M, Doi O, Kodama K, Yokouchi H, Kasugai T, Ishiguro S, Takami K, Nakayama T, Nishisho I. 1997. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. Br J Cancer 75:1302-1308. (Pubitemid 27179820)
11. Hori M, Shimazaki J, Inagawa S, Itabashi M, Hori M. 2002. Over-expression of MDM2 oncoprotein correlates with possession of estrogen receptor alpha and lack of MDM2 mRNA splice variants in human breast cancer. Breast Cancer Res Treat 71:77-83.
12. Iacopetta B. 2003. TP53 mutation in colorectal cancer. Hum Mutat 21:271-276.
13. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, Pramanik A, Selivanova G. 2004. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 10:1321-1328.
14. Iwakuma T, Lozano G. 2003. MDM2, an introduction. Mol Cancer Res 1:993-1000.
15. Kondo I, Iida S, Takagi Y, Sugihara K. 2008. MDM2 mRNA expression in the p53 pathway may predict the potential of invasion and liver metastasis in colorectal cancer. Dis Colon Rectum 51:1395-1402.
16. Lambert JM, Gorzov P, Veprintsev DB, Söderqvist M, Segerbäck D, Bergman J, Fersht AR, Hainaut P, Wiman KG, Bykov VJ. 2009. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 15:376-388.
17. Lengauer C, Green ED, Cremer T. 1992. Fluorescence in situ hybridization of YAC clones after Alu-PCR amplification. Genomics 13:826-828.
18. Lips EH, de Graaf EJ, Tollenaar RA, van Eijk R, Oosting J, Szuhai K, Karsten T, Nanya Y, Ogawa S, van de Velde CJ, Eilers PH, van Wezel T, Morreau H. 2007. Single nucleotide polymorphism array analysis of chromosomal instability patterns discriminates rectal adenomas from carcinomas. J Pathol 212:269-277.
19. Lukas J, Gao DQ, Keshmeshian M, Wen WH, Tsao-Wei D, Rosenberg S, Press MF. 2001. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res 61:3212-3219. (Pubitemid 32691978)
20. Matsukuma S, Yoshihara M, Kasai F, Kato A, Yoshida A, Akaike M, Kobayashi O, Nakayama H, Sakuma Y, Yoshida T, Kameda Y, Tsuchiya E, Miyagi Y. 2006. Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay. J Mol Diagn 8:504-512.
21. Menin C, Scaini MC, De Salvo GL, Biscuola M, Quaggio M, Esposito G, Belluco C, Montagna M, Agata S, D'Andrea E, Nitti D, Amadori A, Bertorelle R. 2006. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 98:285-288.
22. Momand J, Jung D, Wilczynski S, Niland J. 1998. The MDM2 gene amplification database. Nucleic Acids Res 26:3453-3459.
23. Morowitz M, Shusterman S, Mosse Y, Hii G, Winter CL, Khazi D, Wang Q, King R, Maris JM. 2003. Detection of single-copy chromosome 17q gain in human neuroblastomas using real-time quantitative polymerase chain reaction. Mod Pathol 16:1248-1256. (Pubitemid 38018607)
24. Oliva MR, Ripoll F, Muñiz P, Iradi A, Trullenque R, Valls V, Drehmer E, Sáez GT. 1997. Genetic alterations and oxidative metabolism in sporadic colorectal tumors from a Spanish community. Mol Carcinog 18:232-243.
25. Onel K, Cordon-Cardo C. 2004. MDM2 and prognosis. Mol Cancer Res 2:1-8.
26. Polsky D, Bastian BC, Hazan C, Melzer K, Pack J, Houghton A, Busam K, Cordon-Cardo C, Osman I. 2001. HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer Res 61:7642-7646. (Pubitemid 32995060)
27. Rayburn E, Zhang R, He J, Wang H. 2005. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets 5:27-41. (Pubitemid 40321798)
28. Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N. 2005. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 23:7518-7528. (Pubitemid 46291815)
29. Sakuma Y, Matsukuma S, Yoshihara M, Nakamura Y, Noda K, Nakayama H, Kameda Y, Tsuchiya E, Miyagi Y. Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: Confirmation of the correlations with histologic subtypes and gene mutations. 2007. Am J Clin Pathol 128:100-108. (Pubitemid 47121721)
30. Salcedo A, Mayor F Jr., Penela P. 2006. Mdm2 is involved in the ubiquitination and degradation of G-protein-coupled receptor kinase 2. EMBO J 25:4752-4762.
31. Simon R, Struckmann K, Schraml P, Wagner U, Forster T, Moch H, Fijan A, Bruderer J, Wilber K, Mihatsch MJ, Gasser T, Sauter G. 2002. Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene 21:2476-2483.
32. Sobin LH, Wittekind C. 2002. International Union Against Cancer (UICC) TNM Classification of Malignant Tumors, 6th ed. New York: Wiley-Liss. 272 p.
33. Taubert H, Schuster K, Brinck U, Bartel F, Kappler M, Lautenschläger C, Bache M, Trump C, Schmidt H, Holzhausen HJ, Würl P, Schlott T. 2003. Loss of heterozygosity at 12q14- 15 often occurs in stage I soft tissue sarcomas and is associated with MDM2 amplification in tumors at various stages. Mod Pathol 16:1109-1116.
34. Toledo F, Wahl GM. 2006. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 6:909-923.
35. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, Zhao X, Vu BT, Qing W, Packman K, Myklebost O, Heimbrook DC, Vassilev LT. 2006. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 103:1888-1893.
36. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. 2004. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844-848.
37. Vogelstein B, Lane D, Levine AJ. 2000. Surfing the p53 network. Nature 408:307-310.
38. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. 2009. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 9:489-499.
39. Wilkening S, Bermejo JL, Hemminki K. 2007. MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis 28:2262-2267. (Pubitemid 350119563)
40. Yoeli-Lerner M, Yiu GK, Rabinovitz I, Erhardt P, Jauliac S, Toker A. 2005. Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol Cell 20:539-550. (Pubitemid 41668639)
41. Zhu Y, Poyurovsky MV, Li Y, Biderman L, Stahl J, Jacq X, Prives C. 2009. Ribosomal protein S7 is both a regulator and a substrate of MDM2. Mol Cell 35:316-326.